Terumo Gets Its Toe Wet in the US Cardiovascular Market
Terumo is a major device company in Japan, but has to date had little success in building a US business. With the acquisition of 3M's cardiovascular business, is Terumo taking its first major step toward building a greater US presence?
You may also be interested in...
Brief summaries of recent product and clinical developments in the device industry, including developments in Cardiac and Peripheral Devices, Miniature Robotic Devices, and Diabetes Management.
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.